{"id":"NCT01166997","sponsor":"Boston Scientific Corporation","briefTitle":"ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism","officialTitle":"Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2013-04","completion":"2013-05","firstPosted":"2010-07-21","resultsPosted":"2016-10-18","lastUpdate":"2021-07-19"},"enrollment":59,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Submassive Pulmonary Embolism"],"interventions":[{"type":"DEVICE","name":"EkoSonic Endovascular System","otherNames":[]},{"type":"DRUG","name":"Unfractionated heparin","otherNames":[]}],"arms":[{"label":"Ultrasound accelerated thrombolysis","type":"EXPERIMENTAL"},{"label":"Intravenous unfractionated heparin","type":"ACTIVE_COMPARATOR"}],"summary":"The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio â‰¥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.","primaryOutcome":{"measure":"Reduction of RV/LV Ratio","timeFrame":"24 hours","effectByArm":[{"arm":"Unfractionated Heparin (UFH) Alone","deltaMin":0.03,"sd":0.16},{"arm":"Unfractionated Heprin + EkoSonic Procedure","deltaMin":0.3,"sd":0.2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":24},"locations":{"siteCount":10,"countries":["Germany","Switzerland"]},"refs":{"pmids":["24226805"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":29},"commonTop":["Oedema peripheral"]}}